St. Jude Resynchronization ICD Enrollment Trimmed By 150 Patients
This article was originally published in The Gray Sheet
Executive Summary
St. Jude continues to project that its Epic HF resynchronization ICD will not reach the U.S. market until early 2004, despite FDA permission to reduce the required sample size of the pivotal RHYTHM study
You may also be interested in...
CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel
Peak VO2 level is an impractical endpoint to use in clinical trials of cardiac resynchronization therapy (CRT) devices, panelists agreed at a recent Heart Failure Society of America event in Washington, D.C
CRT Should Slow Heart Failure Progression, Not Merely Lift Symptoms – Panel
Peak VO2 level is an impractical endpoint to use in clinical trials of cardiac resynchronization therapy (CRT) devices, panelists agreed at a recent Heart Failure Society of America event in Washington, D.C
St. Jude Relying On ICD Boom To Weather Slowdown In Pacer Sales
St. Jude continues to benefit from the rapidly expanding ICD market, although pacemaker sales are constrained by competition from cardiac resynchronization therapy (CRT) devices for congestive heart failure